Cargando…

Dapagliflozin Attenuates Hyperglycemia Related Osteoporosis in ZDF Rats by Alleviating Hypercalciuria

Recent studies showed that in patients with type 2 diabetes mellitus (T2DM), Sodium-dependent glucose transporters 2 inhibitor (SGLT2I) may cause potential adverse effects on skeleton such as increasing the risk of fracture. This risk is possibly mediated by effects induced by all SGLT2I class drugs...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ji-Yu, Cheng, Yan-Zhen, Yang, Shuang-Li, An, Min, Zhang, Hua, Chen, Hong, Yang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856656/
https://www.ncbi.nlm.nih.gov/pubmed/31781028
http://dx.doi.org/10.3389/fendo.2019.00700
_version_ 1783470613364473856
author Wang, Ji-Yu
Cheng, Yan-Zhen
Yang, Shuang-Li
An, Min
Zhang, Hua
Chen, Hong
Yang, Li
author_facet Wang, Ji-Yu
Cheng, Yan-Zhen
Yang, Shuang-Li
An, Min
Zhang, Hua
Chen, Hong
Yang, Li
author_sort Wang, Ji-Yu
collection PubMed
description Recent studies showed that in patients with type 2 diabetes mellitus (T2DM), Sodium-dependent glucose transporters 2 inhibitor (SGLT2I) may cause potential adverse effects on skeleton such as increasing the risk of fracture. This risk is possibly mediated by effects induced by all SGLT2I class drugs but whether Dapagliflozin aggravates osteoporosis in patients with T2DM remains controversial. Therefore, we designed this study to explore how Dapagliflozin affects the metabolism and the quality of bone in. T2DM animal models The effect of Dapagliflozin on skeleton was evaluated on male ZDF (Zucker Diabetic Fatty) rats—a rat model of diet induced spontaneous T2DM. Dapagliflozin was administrated via gavage at the dosage of 1.0 mg/kg/day. Bone tissue mineral density and the microarchitecture of tibiae were measured with micro-CT and biomechanics characteristic of the femora were tested using a three-point bending test. Serum bone biomarkers and other metabolic parameters were also tested via ELISA or other assays. Our results found that diabetic rats demonstrated symptoms of osteoporosis and Dapagliflozin could help to alleviate these defections caused by diabetes. Compared to the negative controls, the serum CT (calcitonin) level in ZDF rats as well as the uric calcium and phosphate levels were elevated, and these symptoms were alleviated by Dapagliflozin. Tibiae of Dapagliflozin treated rats demonstrated decreased cortical tissue mineral density while trabecular tissue mineral density and mean bone mineral density received a rise when compared to the matched controls. ZDF rats also showed defections in femora stiffness which could be relieved by Dapagliflozin administration. The mechanism of Dapagliflozin affecting bone quality is possibly connected to the suppression of serum calcitonin and excretion of calcium via urine rose by hyperglycemia. In conclusion, Dapagliflozin can prevent osteoporosis in ZDF rats by alleviating hypercalciuria.
format Online
Article
Text
id pubmed-6856656
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-68566562019-11-28 Dapagliflozin Attenuates Hyperglycemia Related Osteoporosis in ZDF Rats by Alleviating Hypercalciuria Wang, Ji-Yu Cheng, Yan-Zhen Yang, Shuang-Li An, Min Zhang, Hua Chen, Hong Yang, Li Front Endocrinol (Lausanne) Endocrinology Recent studies showed that in patients with type 2 diabetes mellitus (T2DM), Sodium-dependent glucose transporters 2 inhibitor (SGLT2I) may cause potential adverse effects on skeleton such as increasing the risk of fracture. This risk is possibly mediated by effects induced by all SGLT2I class drugs but whether Dapagliflozin aggravates osteoporosis in patients with T2DM remains controversial. Therefore, we designed this study to explore how Dapagliflozin affects the metabolism and the quality of bone in. T2DM animal models The effect of Dapagliflozin on skeleton was evaluated on male ZDF (Zucker Diabetic Fatty) rats—a rat model of diet induced spontaneous T2DM. Dapagliflozin was administrated via gavage at the dosage of 1.0 mg/kg/day. Bone tissue mineral density and the microarchitecture of tibiae were measured with micro-CT and biomechanics characteristic of the femora were tested using a three-point bending test. Serum bone biomarkers and other metabolic parameters were also tested via ELISA or other assays. Our results found that diabetic rats demonstrated symptoms of osteoporosis and Dapagliflozin could help to alleviate these defections caused by diabetes. Compared to the negative controls, the serum CT (calcitonin) level in ZDF rats as well as the uric calcium and phosphate levels were elevated, and these symptoms were alleviated by Dapagliflozin. Tibiae of Dapagliflozin treated rats demonstrated decreased cortical tissue mineral density while trabecular tissue mineral density and mean bone mineral density received a rise when compared to the matched controls. ZDF rats also showed defections in femora stiffness which could be relieved by Dapagliflozin administration. The mechanism of Dapagliflozin affecting bone quality is possibly connected to the suppression of serum calcitonin and excretion of calcium via urine rose by hyperglycemia. In conclusion, Dapagliflozin can prevent osteoporosis in ZDF rats by alleviating hypercalciuria. Frontiers Media S.A. 2019-11-05 /pmc/articles/PMC6856656/ /pubmed/31781028 http://dx.doi.org/10.3389/fendo.2019.00700 Text en Copyright © 2019 Wang, Cheng, Yang, An, Zhang, Chen and Yang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Wang, Ji-Yu
Cheng, Yan-Zhen
Yang, Shuang-Li
An, Min
Zhang, Hua
Chen, Hong
Yang, Li
Dapagliflozin Attenuates Hyperglycemia Related Osteoporosis in ZDF Rats by Alleviating Hypercalciuria
title Dapagliflozin Attenuates Hyperglycemia Related Osteoporosis in ZDF Rats by Alleviating Hypercalciuria
title_full Dapagliflozin Attenuates Hyperglycemia Related Osteoporosis in ZDF Rats by Alleviating Hypercalciuria
title_fullStr Dapagliflozin Attenuates Hyperglycemia Related Osteoporosis in ZDF Rats by Alleviating Hypercalciuria
title_full_unstemmed Dapagliflozin Attenuates Hyperglycemia Related Osteoporosis in ZDF Rats by Alleviating Hypercalciuria
title_short Dapagliflozin Attenuates Hyperglycemia Related Osteoporosis in ZDF Rats by Alleviating Hypercalciuria
title_sort dapagliflozin attenuates hyperglycemia related osteoporosis in zdf rats by alleviating hypercalciuria
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856656/
https://www.ncbi.nlm.nih.gov/pubmed/31781028
http://dx.doi.org/10.3389/fendo.2019.00700
work_keys_str_mv AT wangjiyu dapagliflozinattenuateshyperglycemiarelatedosteoporosisinzdfratsbyalleviatinghypercalciuria
AT chengyanzhen dapagliflozinattenuateshyperglycemiarelatedosteoporosisinzdfratsbyalleviatinghypercalciuria
AT yangshuangli dapagliflozinattenuateshyperglycemiarelatedosteoporosisinzdfratsbyalleviatinghypercalciuria
AT anmin dapagliflozinattenuateshyperglycemiarelatedosteoporosisinzdfratsbyalleviatinghypercalciuria
AT zhanghua dapagliflozinattenuateshyperglycemiarelatedosteoporosisinzdfratsbyalleviatinghypercalciuria
AT chenhong dapagliflozinattenuateshyperglycemiarelatedosteoporosisinzdfratsbyalleviatinghypercalciuria
AT yangli dapagliflozinattenuateshyperglycemiarelatedosteoporosisinzdfratsbyalleviatinghypercalciuria